GlassScriptPhysician profile
Stephen Couvillion
NPI 1316980014
$43,144.21
in general payments reported to CMS, 2019-2025
24 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,996 · 2020: $2,014 · 2021: $276 · 2022: $1,240 · 2023: $3,838 · 2024: $2,735 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $6,570 · Food and Beverage: $5,921 · Travel and Lodging: $2,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,600.00 |
| Consulting Fee | $6,570.00 |
| Food and Beverage | $5,921.14 |
| Travel and Lodging | $2,527.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $33,210.11 | 2020-2025 | Susvimo, Vabysmo |
| Alcon Vision LLC | $2,358.16 | 2019-2025 | Constellation, Ngenuity, Centurion |
| Carl Zeiss Meditec, INC. | $2,199.24 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $1,207.81 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $907.77 | 2022-2025 | Ozurdex |
| Alimera Sciences, INC. | $755.58 | 2019-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $502.25 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $329.15 | 2019-2023 | |
| US Retina LLC | $254.69 | 2019 | |
| Ani Pharmaceuticals, INC. | $245.44 | 2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Iridex Corporation | $242.07 | 2022-2024 | |
| Astellas Pharma US INC | $179.86 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $149.61 | 2023-2024 | Miebo, Xiidra, Xipere |
| Ivantis, INC | $133.90 | 2019 | |
| Allergan, INC. | $106.35 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurotech Pharmaceuticals, INC. | $100.51 | 2025 | |
| Harrow Eye, LLC | $93.52 | 2025 | Iheezo |
| Biogen, INC. | $88.55 | 2022-2025 | Byooviz |
| Abb Con-Cise Optical Group LLC | $61.56 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.08 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,360.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Couvillion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.